Unique ID issued by UMIN | UMIN000030265 |
---|---|
Receipt number | R000034565 |
Scientific Title | A single arm, open-label study evaluating the safety and efficacy of ra148 in patients with atopic dermatitis. |
Date of disclosure of the study information | 2017/12/05 |
Last modified on | 2019/03/25 15:30:33 |
A single arm, open-label study evaluating the safety and efficacy of ra148 in patients with atopic dermatitis.
A single arm, open-label study evaluating the safety and efficacy of ra148 in patients with atopic dermatitis.
A single arm, open-label study evaluating the safety and efficacy of ra148 in patients with atopic dermatitis.
A single arm, open-label study evaluating the safety and efficacy of ra148 in patients with atopic dermatitis.
Japan |
Atopic dermatitis
Dermatology | Adult | Child |
Others
NO
To confirm the clinical efficacy and safety of topical cream (ra148) in the treatment of atopic dermatitis.
Safety,Efficacy
Evaluation of usefulness of long-term (12mo) application of ra148 on atopic disease by the principal doctor.
1) Severity classification (simple method) of atopic dermatitis developed by the advisory committee of atopic dermatitis severity classification of Japanese Dermatological Association at the test site.
2) Evaluation of the digital images of the test site.
3) Questionnaires for QOL assessment in atopic dermatitis.
4) Evaluation of the patient's diaries (Medication compliance, Subjective symptoms, The degree of itchiness, etc.).
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Apply topical moisturizing ingredient containing cream (ra148) twice a day for 12 months.
16 | years-old | <= |
49 | years-old | >= |
Male and Female
1) Patients with atopic dermatitis who has mild or moderate rash and visits MIE HIFUKA CLINIC.
2) Those who can acquire written consent based on the voluntary intention before starting the study (For minors under the age of 20, in addition to their consent, the consent of the guardian in writing shall also be obtained).
Priority is given to those who normally use Hirudoid (Maruho Co., Ltd.) formulation as a humectant.
1) Patients with severe skin disorders on test site (both arms) and deemed inappropriate to participate in this study by the doctor.
2) Patients who have a history of hypersensitivity to heparin analog preparation.
3) Pregnant or lactating patients. Patients with suspicion of pregnancy.
4) Patients deemed inappropriate to participate in this study by the principal doctor or investigators.
5) Patients with hemorrhagic blood disease; e.g. Hemophilia, Thrombocytopenia, Purpura, etc.
6) Patients who are expected to promote serious consequences with minimal bleeding.
7) Patients who have undergone climacteric disorder or postmenopausal "hormone replacement therapy"
12
1st name | |
Middle name | |
Last name | Kenichi Isoda, M.D., Ph.D. |
MIE HIFUKA CLINIC
Chief of Clinic
633-61 Takano-o-cho Tsu-shi Mie, 514-2221, JAPAN
059-230-8787
isoda@miehifu.jp
1st name | |
Middle name | |
Last name | Azumi Nagasawa, Ph.D. |
Kao Corporation
R&D - Core Technology -
2606 Akabane Ichikai-machi Haga-gun Tochigi 321-3497, JAPAN
0285-68-7706
nagasawa.azumi@kao.com
MIE HIFUKA CLINIC
Kao Corporation
Profit organization
NO
みえひふ科クリニック(三重県)
2017 | Year | 12 | Month | 05 | Day |
Unpublished
Completed
2017 | Year | 10 | Month | 17 | Day |
2017 | Year | 10 | Month | 17 | Day |
2017 | Year | 12 | Month | 18 | Day |
2019 | Year | 02 | Month | 20 | Day |
2017 | Year | 12 | Month | 05 | Day |
2019 | Year | 03 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034565
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |